June 2025 | BioLink Therapeutics, India

BioLink Therapeutics is proud to announce a major breakthrough in its mission to bridge global healthcare innovation with local accessibility — the development of India’s first-ever high-specificity liquid biopsy platform for rapid cancer screening at the point of care. This pioneering technology is set to transform early cancer detection for millions, starting with four of the most prevalent and deadly cancers in India: breast, colorectal, lung, and prostate cancer.

In a country where cancer diagnosis is often delayed due to the unavailability of rapid, reliable diagnostics, BioLink’s 15-minute point-of-care liquid biopsy test offers a game-changing solution. Designed for use in primary health centers and urban clinics alike, the test is non-invasive, highly specific, and easy to administer, allowing for cancer screening during a single patient visit — with no need for complex laboratory infrastructure.

The prototype has already been developed, and over 5,000 patient samples have been successfully tested and validated, with results published in peer-reviewed journals. This robust clinical evidence highlights the platform’s exceptional diagnostic performance, ensuring confidence among healthcare providers and patients.

BioLink Therapeutics has entered into a strategic international collaboration with a U.S.-based startup to bring a disruptive healthcare technology to India. Leading the charge in technology transfer, optimization, and large-scale deployment, BioLink is committed to integrating this cutting-edge innovation into the Indian healthcare ecosystem. Our team—comprising globally trained scientists and entrepreneurs—is especially focused on extending its impact to underserved communities, where early detection can be life-saving.

BioLink Therapeutics now seeks venture capital partners who share our vision of democratizing access to cutting-edge diagnostics. With a scalable platform, proven clinical validity, and strong commercial potential, our liquid biopsy program is not just a technological milestone — it’s a business opportunity to lead India’s precision oncology revolution.

Let’s work together to take this breakthrough to every corner of India — and beyond.

For investment inquiries, contact: kindly reach us through
🌐 www.biolinktherapeutics.com